- Clinical Pipeline
- Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
- Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
- Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
- ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
- ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
- Partnered Products and Programs
- Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
- Balversa® (erdafitinib) FGFr inhibitor (Oncology)
- Truqap™ PKB/Akt Inhibitor (Oncology)
- Multiple Targets and Therapeutic Areas
- Pyramid™ Discovery Platform
- Oncology and CNS Discovery
- Sustaining Innovation
As a member of the Otsuka group, Astex shares the global vision of a commitment to creativity and innovation through the discovery, development and commercialization of new products and innovative solutions for better health worldwide.
Our drug discovery research and preclinical development teams utilize our cutting-edge technology platform in the relentless pursuit of innovative solutions that address the extensive and complex challenges in oncology and diseases of the CNS.
Our products will be developed and commercialized through Otsuka operating subsidiaries in the major markets worldwide and through selective strategic collaborations with other pharma partners globally.
Preclinical and
Clinical Pipeline
As a leader in innovative small-molecule drug discovery, we have established a strong portfolio of proprietary and partnered molecularly targeted drug products in clinical development.
Oncology and CNS discovery
We are accelerating new breakthroughs in oncology and in neuroscience research through our discovery programs and collaborative, open innovation approach.
Pyramid™ Discovery platform
New small molecule targeted therapies are generated using our proprietary Fragment Based Drug Discovery platform, Pyramid™.
Sustaining Innovation
Our Sustaining Innovation Postdoctoral Training Programs are important in enhancing our in-house research capabilities and scientific culture.
Clinical
Pipeline
As a leader in innovative small-molecule drug discovery, we have established a strong portfolio of proprietary and partnered molecularly targeted drug products in clinical development.
Oncology and CNS discovery
We are accelerating new breakthroughs in oncology and in neuroscience research through our discovery programs and collaborative, open innovation approach.
Pyramid™ Discovery platform
New small molecule targeted therapies are generated using our proprietary Fragment Based Drug Discovery platform, Pyramid™.
Sustaining Innovation
Our Sustaining Innovation Postdoctoral Training Programs are important in enhancing our in-house research capabilities and scientific culture.
Presentations & Publications
Access a wide range of resource that provide detailed information on our products, programs and collaborations.
Operations
Located in Cambridge, UK, our business headquarters and research facilities house a world-class team of drug discovery research and preclinical development scientists.
© Astex Pharmaceuticals
All rights reserved
